Shire (SHPG) PT Set at $222.00 by Cantor Fitzgerald
Shire (NASDAQ:SHPG) has been given a $222.00 target price by stock analysts at Cantor Fitzgerald in a research report issued on Tuesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 55.58% from the company’s current price.
Several other equities research analysts have also weighed in on SHPG. Barclays lowered Shire from an “overweight” rating to an “equal weight” rating in a research report on Friday, August 11th. Jefferies Group reaffirmed a “hold” rating and set a $206.00 price target (down previously from $216.00) on shares of Shire in a research report on Wednesday, August 9th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $213.00 price target on shares of Shire in a research report on Monday, October 2nd. FBR & Co reaffirmed a “buy” rating and set a $201.00 price target on shares of Shire in a research report on Monday, October 30th. Finally, Liberum Capital raised Shire from a “hold” rating to a “buy” rating in a research report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company’s stock. Shire presently has an average rating of “Buy” and an average target price of $212.18.
Shares of Shire (NASDAQ SHPG) opened at $142.69 on Tuesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98. Shire has a 12-month low of $137.17 and a 12-month high of $192.15. The firm has a market capitalization of $43,423.72, a PE ratio of 9.94, a PEG ratio of 0.80 and a beta of 1.59.
Shire (NASDAQ:SHPG) last issued its earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.64 by $0.17. Shire had a return on equity of 14.41% and a net margin of 10.95%. The business had revenue of $3.70 billion for the quarter. During the same period last year, the business posted $3.17 EPS. Shire’s revenue was up 7.1% on a year-over-year basis. research analysts forecast that Shire will post 15 earnings per share for the current fiscal year.
Several hedge funds have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC purchased a new position in shares of Shire in the 3rd quarter valued at approximately $159,000. Sterling Capital Management LLC grew its stake in shares of Shire by 26,182.4% in the 3rd quarter. Sterling Capital Management LLC now owns 474,397 shares of the biopharmaceutical company’s stock valued at $72,649,000 after purchasing an additional 472,592 shares during the last quarter. Afam Capital Inc. grew its stake in shares of Shire by 3.0% in the 3rd quarter. Afam Capital Inc. now owns 30,761 shares of the biopharmaceutical company’s stock valued at $4,711,000 after purchasing an additional 882 shares during the last quarter. Neuberger Berman Group LLC grew its stake in shares of Shire by 16.4% in the 3rd quarter. Neuberger Berman Group LLC now owns 21,789 shares of the biopharmaceutical company’s stock valued at $3,337,000 after purchasing an additional 3,076 shares during the last quarter. Finally, Lumbard & Kellner LLC grew its stake in shares of Shire by 46.9% in the 3rd quarter. Lumbard & Kellner LLC now owns 26,685 shares of the biopharmaceutical company’s stock valued at $4,087,000 after purchasing an additional 8,515 shares during the last quarter. Institutional investors own 20.28% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Shire (SHPG) PT Set at $222.00 by Cantor Fitzgerald” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://theolympiareport.com/2017/12/07/shire-shpg-pt-set-at-222-00-by-cantor-fitzgerald.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.